Personalized management of essential thrombocythemia - Application of recent evidence to clinical practice

Leukemia

Volumn 27, Issue 8, 2013, Pages 1617-1620

  Tefferi, A ^a   Barbui, T ^b  

^a MAYO CLINIC   (United States)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

essential; myelofibrosis; myeloproliferative; polycythemia; thrombocythemia

Indexed keywords

ACETYLSALICYLIC ACID; BUSULFAN; HYDROXYUREA; PEGINTERFERON;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EVIDENCE BASED PRACTICE; HUMAN; LEUKOCYTOSIS; LOW DRUG DOSE; MORBIDITY; MYELOFIBROSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; SYSTEMIC THERAPY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT DURATION; TURNOVER TIME; VEIN THROMBOSIS; WORLD HEALTH ORGANIZATION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROGNOSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84881477148     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.99     Document Type: Review

References (24)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
2. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
3. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013; e-pub ahead of print 7 March 2013; doi: 10.1038/leu.2013.74.
4. Michiels JJ, Berneman Z, Schroyens W, Kutti J, Swolin B, Ridell B et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 2004; 83: 504-512. (Pubitemid 39144751)
5. Boissinot M, Garand R, Hamidou M, Hermouet S. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 2006; 108: 1781-1782. (Pubitemid 44316158)
6. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85: 62-69.
7. Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol 2012; 87: 203-204.
8. Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlue J et al. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009; 37: 1186-1193 e1187.
9. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179-3184.
10. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012; 26: 716-719.
11. Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Mullauer L et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 2012; 87: 669-672.
12. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120: 1197-1201.
13. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 285-293.
14. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombo-cythemia: an international study of 891 patients. Blood 2011; 117: 5857-5859.
15. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120: 5128-5133; quiz 5252.
16. Tefferi A. Overcoming "aspirin resistance" in MPN. Blood 2012; 119: 3377-3378.
17. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-3603.
18. Di Minno MN, Lupoli R, Palmieri NM, Russolillo A, Buonauro A, Di Minno G. Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. Thromb Res 2011; 129: 341-344.
19. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G et al. The contribution of cyclooxygenase-1 and-2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115: 1054-1061.
20. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185-191.
21. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599. (Pubitemid 47280339)
22. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368: 22-33.
23. Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116: 1205-1210quiz 1387.
24. Barbui T. How to manage children and young adults with myeloproliferative neoplasms. Leukemia 2012; 26: 1452-1457.